info@ufovax.com | CONTACT US

  • About Us
    • The Company
    • The Management
    • The Scientific Advisory Board
  • Technologies
    • The 1c-SApNP Platform Technology
    • Coronavirus Vaccine
    • HIV Vaccine
    • HCV Vaccine
    • RSV/hMPV Vaccines
    • Ebola Vaccine
    • Malaria Vaccine
    • Tuberculosis Vaccine
  • News
  • Publications
  • Investors
  • Site
  • WE HAVE SUCCESSFULLY EXTENDED

    Our 1c-SApNP Platform Technology
    to Vaccine for COVID-19

    Clinical trials planned for early 2021

     

  • Another 1c-SApNP Success

    Science Advances publishes a proof-of-concept-paper
    for nanoparticle HCV vaccine co-sponsored by NIH & Ufovax

  • Our patented 1c-SApNP Platform Technology

    has delivered promising vaccine candidates to address global health challenges
    such as HIV, HCV, Ebola, RSV, Coronavirus, Malaria & Tuberculosis

Latest News

Ufovax Extends Its Intellectual Property Portfolio to Include a Patent Covering the Design of an Optimized Antigen For COVID-19

December 1, 2020

WILMINGTON, Del.–(BUSINESS WIRE)–Ufovax, LLC, (Ufovax), a vaccine biotechnology company based on the Single-component Self-Assembling protein NanoParticle (1c-SApNP) vaccine design and manufacturing platform invented by Associate Professor Jiang Zhu, PhD, of Scripps Research (La Jolla, CA), has extended its intellectual property portfolio to include an exclusive… [Read more]

Ufovax Announces Its Self-Assembling NanoParticles as the Next-Generation Vaccine Solution for COVID-19

September 17, 2020

WILMINGTON, Del.–(BUSINESS WIRE)–Ufovax, LLC, (Ufovax), a vaccine biotechnology company based on the patented One-component Self-Assembling protein NanoParticle® (1c-SApNP®) vaccine design and manufacturing platform invented by Associate Professor Jiang Zhu, PhD, of Scripps Research (La Jolla, CA), announced the advancement toward Phase I clinical trials of its next-generation… [Read more]

About Ufovax

Founded in early 2018, Ufovax, a spin-off vaccine company from Scripps Research, La Jolla, CA, employs patented single-component self-assembling protein nanoparticle (1c-SApNP) platform technology developed by Professor Jiang Zhu of Scripps Research to develop and commercialize B-cell focused, rapid antibody-eliciting, preventive vaccines for the most challenging diseases around the world.

Our 1c-SApNP technology streamlines vaccine development and has delivered promising vaccine candidates to address global health challenges such as HIV, RSV/hMPV, PIV1-5, Ebola/Marburg, Lassa, coronaviruses including SARS-CoV, MERS-CoV and SARS-CoV-2, HCV, ZIKV/DENV, and non-viral diseases such as Malaria and Tuberculosis.

Ufovax

3801 Kennett Pike
Ste. A101, #4482
Wilmington, DE
19807-9998
info@ufovax.com

  • The Company
  • The Management
  • The Scientific Advisory Board
  • News
  • Investors
  • Contact Us
  • The 1c-SApNP Platform Technology
  • Coronavirus Vaccine
  • HIV Vaccine
  • HCV Vaccine
  • RSV/hMPV Vaccines
  • Ebola Vaccine
  • Malaria Vaccine
  • Tuberculosis Vaccine

© Ufovax 2021 | Created by TinyFrog Technologies